BioArctic Past Earnings Performance
Past criteria checks 0/6
BioArctic's earnings have been declining at an average annual rate of -12.6%, while the Biotechs industry saw earnings growing at 13.4% annually. Revenues have been growing at an average rate of 3.4% per year.
Key information
-12.6%
Earnings growth rate
-12.5%
EPS growth rate
| Biotechs Industry Growth | 0.7% |
| Revenue growth rate | 3.4% |
| Return on equity | -9.5% |
| Net Margin | -29.5% |
| Next Earnings Update | 14 Nov 2024 |
Recent past performance updates
Recent updates
BioArctic AB (publ) (STO:BIOA B) Consensus Forecasts Have Become A Little Darker Since Its Latest Report
Sep 01
Need To Know: The Consensus Just Cut Its BioArctic AB (publ) (STO:BIOA B) Estimates For 2024
Aug 15Revenues Tell The Story For BioArctic AB (publ) (STO:BIOA B)
Apr 13News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 19News Flash: 6 Analysts Think BioArctic AB (publ) (STO:BIOA B) Earnings Are Under Threat
Feb 03Investors Interested In BioArctic AB (publ)'s (STO:BIOA B) Revenues
Dec 23With EPS Growth And More, BioArctic (STO:BIOA B) Makes An Interesting Case
Nov 12BioArctic AB (publ) (STO:BIOA B) Analysts Are Way More Bearish Than They Used To Be
Jul 21Analysts Have Lowered Expectations For BioArctic AB (publ) (STO:BIOA B) After Its Latest Results
Jul 15New Forecasts: Here's What Analysts Think The Future Holds For BioArctic AB (publ) (STO:BIOA B)
Jul 07Things Look Grim For BioArctic AB (publ) (STO:BIOA B) After Today's Downgrade
May 06Companies Like BioArctic (STO:BIOA B) Can Afford To Invest In Growth
Mar 13Broker Revenue Forecasts For BioArctic AB (publ) (STO:BIOA B) Are Surging Higher
Nov 30We're Not Worried About BioArctic's (STO:BIOA B) Cash Burn
Sep 16We're Interested To See How BioArctic (STO:BIOA B) Uses Its Cash Hoard To Grow
Apr 04We Think BioArctic (STO:BIOA B) Can Easily Afford To Drive Business Growth
Dec 05BioArctic AB (publ) (STO:BIOA B) Shares Could Be 42% Below Their Intrinsic Value Estimate
Sep 15BioArctic (STO:BIOA B) Is In A Strong Position To Grow Its Business
Aug 23Revenue & Expenses Breakdown
How BioArctic makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 299 | -88 | 232 | 58 |
| 31 Mar 24 | 252 | -122 | 258 | 16 |
| 31 Dec 23 | 616 | 229 | 251 | 0 |
| 30 Sep 23 | 607 | 259 | 188 | 88 |
| 30 Jun 23 | 617 | 270 | 182 | 88 |
| 31 Mar 23 | 619 | 327 | 151 | 47 |
| 31 Dec 22 | 229 | -11 | 149 | 0 |
| 30 Sep 22 | 232 | 28 | 131 | 0 |
| 30 Jun 22 | 18 | -147 | 110 | 0 |
| 31 Mar 22 | 21 | -135 | 104 | 0 |
| 31 Dec 21 | 26 | -120 | 97 | 0 |
| 30 Sep 21 | 30 | -114 | 95 | 0 |
| 30 Jun 21 | 37 | -97 | 89 | 0 |
| 31 Mar 21 | 34 | -101 | 87 | 0 |
| 31 Dec 20 | 65 | -69 | 86 | 0 |
| 30 Sep 20 | 84 | -72 | 87 | 0 |
| 30 Jun 20 | 93 | -60 | 87 | 0 |
| 31 Mar 20 | 252 | 78 | 94 | 0 |
| 31 Dec 19 | 283 | 88 | 91 | 0 |
| 30 Sep 19 | 779 | 441 | 101 | 0 |
| 30 Jun 19 | 852 | 475 | 101 | 0 |
| 31 Mar 19 | 729 | 380 | 91 | 0 |
| 31 Dec 18 | 722 | 382 | 89 | 0 |
| 30 Sep 18 | 257 | 58 | 78 | 0 |
| 30 Jun 18 | 197 | 32 | 77 | 0 |
| 31 Mar 18 | 194 | 29 | 83 | -17 |
| 31 Dec 17 | 157 | 15 | 69 | 0 |
| 30 Sep 17 | 193 | 78 | 54 | 22 |
| 30 Jun 17 | 160 | 71 | 41 | 31 |
| 31 Mar 17 | 127 | 64 | 17 | 60 |
| 31 Dec 16 | 106 | 58 | 16 | 54 |
| 31 Dec 15 | 42 | 4 | 6 | 38 |
Quality Earnings: BIOA B is currently unprofitable.
Growing Profit Margin: BIOA B is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: BIOA B is unprofitable, and losses have increased over the past 5 years at a rate of 12.6% per year.
Accelerating Growth: Unable to compare BIOA B's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: BIOA B is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-13.6%).
Return on Equity
High ROE: BIOA B has a negative Return on Equity (-9.5%), as it is currently unprofitable.